Abstract
The possibility of altering the course of prostatic cancer by immunologic means requires a clear understanding of the host-tumor relationship in this disease. Available data suggest that prostatic tumors contain both prostate-specific and tumor-specific antigens, although evidence on the latter is still debatable. Patients with prostatic cancer often show nonspecific depression of their cell-mediated immunocompetence, as do patients with many other forms of cancer. The question of whether prostatic cancers are immunogenic; that is, whether they elicit a specific immunologic response, remains unanswered.
Original language | English (US) |
---|---|
Pages (from-to) | 107-113 |
Number of pages | 7 |
Journal | Seminars in oncology |
Volume | 3 |
Issue number | 2 |
State | Published - Jun 1976 |
ASJC Scopus subject areas
- Hematology
- Oncology